Cytomos

Unlock the future of cell analysis with Celledonia

10 June 2024 – Meet Celledonia, the new and revolutionary benchtop cell analyser that will inform and expedite your bioprocesses and turn your data into actionable insights. TechBio company Cytomos (www.cytomos.com) today announces the launch of its much-anticipated flagship benchtop solution Celledonia, which uses the company’s patented AuraCyt platform. Celledonia – a benchtop cell analyser...

Cytomos showcases groundbreaking new platformfor advanced cell analytics at ISCT 2024

22 May 2024 – At this year’s annual meeting of the International Society for Cell & Gene Therapy (ISCT), TechBio company Cytomos (www.cytomos.com) will be showcasing Celledonia – its flagship technology that utilises the company’s patented AuraCyt platform and is set to revolutionise complex biologics. Cytomos‘ AuraCyt platform closely monitors a broad range of cell...

Cytomos offers sneak preview of flagship technologyat the London Biotechnology Show 2024

1 May 2024 – TechBio company Cytomos (www.cytomos.com) will be giving visitors to this year’s London Biotechnology Show a sneak preview of Celledonia – its flagship technology that utilises the company’s patented AuraCyt platform. Cytomos’ AuraCyt platform has the potential to revolutionise cell analytics, which in turn could transform life sciences. The platform closely monitors...

Cytomos’s chief commercial and innovation officer co-chairs biannual conference advancing cell and gene therapies

Special focus on advancements, trends, disruption and enabling technologies that increase robustness and decrease production costs 30 January 2024 – TechBio company, Cytomos (www.cytomos.com) is pleased to announce that Dr Fernanda Masri, the company’s chief commercial and innovation officer, and former head of Innovation Manufacturing and Collaborations at Cell and Gene Therapy Catapult, will co-chair...

Cytomos appoints new Chief Commercial and Innovation Officer and Techno-Commercial Adviser: Driving the commercialisation strategy as the company evolves from an R&D to a product-based business

23 January 2024 – TechBio company, Cytomos (www.cytomos.com) is pleased to announce the appointment of Dr Fernanda Masri as chief commercial and innovation officer and Dr Christel Fenge as techno-commercial adviser. In her new role, Fernanda will spearhead Cytomos’ commercialisation strategy, as the company rapidly evolves the technology into a commercial product platform suitable from early...

Cytomos unveils patented AuraCyt brand and launches new website for its transformative cell analysis technology

15 December 2023 – Biotech company, Cytomos (www.cytomotos.com) is pleased to announce the creation of its newly named AuraCyt™ cell analysis technology brand and the launch of its enhanced website www.cytomos.com – encapsulating the transformative R&D benefits of its ground-breaking cell analysis technology. AuraCyt provides information on cell properties that is set to revolutionise analytical...

Cytomos selected to showcase CDS cell analysis technology at BIA’s BioProcessUK Dragon’s Den session

23 October 2023 – Biotech company, Cytomos (www.cytomotos.com) is pleased to announce that it has been selected to showcase its dielectric spectroscopy (CDS) platform at the BIA’s BioProcessUK Dragon’s Den special session focused on next generation analytical technologies, taking place on day two of this year’s annual conference: 30 November. Cytomos’ CSO, Dr Lindsay Fraser,...
Middle Wing Building University of Edinburgh Easter Bush Campus Roslin EH25 9RG Scotland